BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a notice of allowance from the Japanese Patent Office for a patent linked to its ThermoStem® Program. This notice, issued on January 26, 2022, covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells, aimed at delivering metabolically active cells for treating metabolic disorders. CEO Lance Alstodt emphasized this strengthens their global patent portfolio and highlights ThermoStem® as a viable treatment for diabetes and obesity, addressing significant unmet medical needs.
- Notice of allowance from Japanese Patent Office enhances intellectual property for ThermoStem®.
- Patent covers innovative implantable three-dimensional scaffolds and brown adipocytes.
- Strengthens BioRestorative's position in metabolic disorder treatments, potentially increasing market credibility.
- None.
Notice of Allowance Grants Protection for Generating Implantable
Three-Dimensional Scaffolds
MELVILLE, N.Y., Feb. 02, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Japanese Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® Program. The notice of allowance was issued on January 26, 2022 and is related to a new patent application not previously announced.
Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes from human brown adipose-derived stem cells. The combination of scaffolds as a delivery system and brown adipose derived stem cells provides the ability to deliver metabolically active cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders.
“We continue to see success developing a comprehensive global patent portfolio for ThermoStem® and this latest notice of allowance further strengthens our overall IP position in using scaffolds as a delivery system." said Lance Alstodt, the Company’s CEO "The claims of this application are the result of BioRestorative’s expertise in applying cell therapy to treat metabolic disorders. They underscore the potential value of ThermoStem® as a novel treatment for diseases such as diabetes and obesity, which represent major unmet needs."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Email: ir@biorestorative.com
FAQ
What is the significance of the patent allowance for BioRestorative Therapies (BRTX)?
When was the notice of allowance issued for the ThermoStem® patent?
What does the ThermoStem® Program focus on?
How might the patent impact BioRestorative's stock performance (BRTX)?
